Response and survival of dogs with proteinuria (UPC > 2.0) treated with angiotensin converting enzyme inhibitors

J Vet Intern Med. 2023 Nov-Dec;37(6):2188-2199. doi: 10.1111/jvim.16864. Epub 2023 Oct 10.

Abstract

Background: Angiotensin-converting enzyme inhibitors (ACEi) are a recommended treatment for glomerular proteinuria. Frequency of response to ACEi and the association of achieving proposed urine protein-to-creatinine ratio (UPC) targets on survival is unknown.

Objectives: To determine response rates to ACEi therapy and whether a positive response is associated with improved survival.

Animals: Eighty-five dogs with proteinuria (UPC > 2.0).

Methods: Retrospective study including dogs (UPC > 2.0) prescribed an ACEi for treatment of proteinuria. Baseline creatinine, albumin, cholesterol, UPC, and systolic blood pressure were recorded, and cases reviewed to track UPC. Treatment response was defined as achieving a UPC of <0.5 or reduction of ≥50% from baseline within 3 months. Outcome data were collected to determine overall and 12-month survival.

Results: Thirty-five (41%) dogs responded to ACEi treatment. Treatment response was statistically associated with both median survival time (664 days [95% confidence interval (CI): 459-869] for responders compared to 177 [95% CI: 131-223] for non-responders) and 12-month survival (79% responders alive compared to 28% non-responders). Baseline azotemia or hypoalbuminemia were also associated with a worse prognosis, with odds ratios of death at 12 months of 5.34 (CI: 1.85-17.32) and 4.51 (CI: 1.66-13.14), respectively. In the 25 dogs with normal baseline creatinine and albumin, response to treatment was associated with 12-month survival (92% responders alive compared to 54% non-responders, P = .04).

Conclusions and clinical importance: When the UPC is >2.0, achieving recommended UPC targets within 3 months appears to be associated with a significant survival benefit. Response to treatment is still associated with survival benefit in dogs with less severe disease (no azotemia or hypoalbuminemia).

Keywords: benazepril; enalapril; glomerular; urine protein creatinine ratio (UPC).

MeSH terms

  • Albumins
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Animals
  • Azotemia* / drug therapy
  • Azotemia* / veterinary
  • Creatinine
  • Dog Diseases* / drug therapy
  • Dogs
  • Hypoalbuminemia* / drug therapy
  • Hypoalbuminemia* / veterinary
  • Proteinuria / drug therapy
  • Proteinuria / veterinary
  • Retrospective Studies

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Creatinine
  • Albumins